Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 8012345...102030...Last »

AstraZeneca Asthma Drug Fails Late-Stage Trials

AstraZeneca and its MedImmune division announced two Phase III trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.

Read More »

Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

Read More »

AstraZeneca, Incyte plan pivotal lung cancer trial

AstraZeneca stepped up its bet on immunotherapy combo treatments to fight lung cancer by signing a deal with Incyte as they will start a final-stage study in 2018.

Read More »

AbbVie Touts Late-Stage Psoriasis Drug Trial Data

AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster Humira or J&J’s Stelara in treating moderate-to-severe chronic plaque psoriasis.

Read More »

Amgen Discontinues Quest for New CETP Heart Drug

In the company’s third-quarter 2017 report, Amgen Inc. announced it scrapped internal development of AMG 899, an oral CETP inhibitor it acquired in the $1.2 billion deal for Netherlands-based Dezima Pharma BV.

Read More »

Gilead Shows Off Mid-Stage NASH Data

Gilead Sciences released results from a Phase II clinical trial of GS-0976 for nonalcoholic steatohepatitis (NASH).

Read More »

DBV Allergy Drug Flunked Phase III Test

DBV Technologies’ Phase III peanut allergy trial failed to show a statistically significant response against placebo.

Read More »

DURECT Pain Med Fails Phase III

DURECT Corporation announced that its Posimir (SABER – Bupivacaine) for post-surgical pain failed a Phase III clinical trial.

Read More »

Celgene Ends Two Phase III Trials

Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710 million deal three years ago following an interim data analysis.

Read More »

Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumors

An experimental cancer drug discovered by Hutchison China MediTech demonstrated promising activity in shrinking tumors in lung cancer patients whose disease had worsened following treatment with approved medicines.

Read More »

Pfizer Touts Lung Cancer, Brain Tumor Data

Mid-stage data shows that Pfizer’s lorlatinib could provide benefits to lung cancer patients who exhibit related brain tumors.

Read More »

Exelixis Cancer Drug Meets Goals in Phase III Trial

Exelixis’s Cabometyx (cabozantinib) hit key endpoints of overall survival in its Phase III liver cancer trial.

Read More »

2017 Annual Report: Top 50 Companies – The Corner Turned

For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.

Read More »

Merck not seeking cholesterol treatment approval

Merck & Co. Inc. will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings.

Read More »

Lilly’s lung cancer drug fails key study goal

Eli Lilly’s drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial.

Read More »

China to accept overseas trial data

China plans to accept data from overseas clinical trials to speed up approvals of drugs, a potential boon for international drugmakers as well as patients.

Read More »

Bayer Halts Phase III Study on New Xarelto Indication

Bayer and its developmental partner Janssen Research & Development are calling it quits on a Phase III stroke prevention study for the blockbuster anti-clotting drug Xarelto.

Read More »

Phase III Trial Success for Motif Bio’s Iclaprim

Motif Bio’s Phase III drug candidate iclaprim hit primary endpoints in treating patients with acute bacterial skin and skin structure infections (ABSSSI).

Read More »

RedHill Biopharma’s bowel syndrome drug data fails to impress investors

RedHill Biopharma Ltd. said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.

Read More »

Oxford team to test universal flu vaccine

A seasonal flu vaccine that would be the world’s first to fight all types of the virus will be tested in a two-year study involving 2,000+ patients by Oxford researchers.

Read More »

Page 3 of 8012345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2017 Focus: Ad Agency Roundtable and more!


Ad Right Bottom

Main Navigation